









## ENSCCA / Precision-BTC-Network Joint Meeting

July 1<sup>st</sup> - 2<sup>nd</sup>, 2024

Jagiellonian University, Faculty of Law & Administration Krupnicza 33A , Krakow, PL

July 1st		
TIME (CET)	TITLE	SPEAKER
08:00-08:45	REGISTRATION	
08:45-9:00	WELCOME from the ENSCCA/COST	C. Braconi / R. Macias
	WELCOME from the local committee	J. Kotlinowski
9:00-10:45	Update on Biliary Tract Cancers (in partnership with ENSCCA/ILCA/EASL/ESMO)	
	CHAIRS	L. Rimassa / A. Saborowski
09:00-09:10	CCA: A brief overview	S. Roessler
09:10-09:25	Role of Endoscopy in Diagnosis and Treatment of Biliary Cancers	L. Krupa
09:25-09:40	Immunotherapy in BTC	A. Vogel
09:40-09:55	Local Therapies for Biliary Cancer: Are we there yet?	J. Edeline
09:55-10:10	BTC: A disease for personalized targeted therapies	T. Macarulla
10:10-10:35	PANEL DISCUSSION (with the addition of)	T. Kendall
10:35-10:50	COFFEE BREAK	
10:50-11:15	Presentation of the ENSCCA / ICRN / Precision-BTC consensus	C. Braconi / J. Valle
11:15-11:25	Experience from Previous COST Action: The example of Euro-Cholangio-Net	V. Cardinale
11:30-13:00	BTC Characterization through a Pan-European Collaborative Effort	
	CHAIRS	V. Cardinale / M. Afonso
11:30-11:45	European Clinical Registry: Where we are and where we are going	J. Banales / L. Izquierdo
11:45-12:00	European Morphological Registry of Cholangiocarcinoma: An update	G. Carpino / T. Kendall
12:00-12:15	International Registry on Gallbladder Cancer	M. Krawczyk
12:15-12:25	Ampullary Lesions: Considerations for an international registry	M. Hollenbach
12:25-12:35	Gold Award recipient: Refinement of histologic subtypes and identification of biomarkers linked to	D. Overi
12:35-13:00	unfavourable prognosis in CCA PANEL DISCUSSION (with the addition of)	A. Lamarca / C. Gabbi / M. Cornille
13:00-14:00	LUNCH	
14:00-15:30	Personalizing the Early Diagnosis of Biliary Cancer	
	CHAIRS	S. Roessler / C. Gabbi
14:00-14:15	Patients at Risk: Learning about primary sclerosing cholangitis	C. Schramm
14:15-14:30	Novel Biomarkers for Early Diagnosis: The role of metabolomics	P. Rodrigues
14:30-14:45	Novel Pre-clinical Models to Study the Evolution from PSC to CCA	L. Boulter
14:45-14:55	The Asp-PSC-Trial: A platform for translational analyses in early diagnosis	S. Khan
14:55-15:05	International Consortium for the Genetics of Biliary Tract Cancers: A cholangiocarcinoma GWAS study	L.R. Roberts
15:05-15:30	PANEL DISCUSSION (with the addition of)	J. Banales / A. Forner
15:30-15:45	BREAK & GROUP PHOTO	
15:45-17:15	Precision Therapeutic Strategies in Biliary Tract Cancers	
	CHAIRS	A. Lamarca / P. Olthof
15:45-16:00	Neoadjuvant Treatment in BTC	L. Rimassa
16:00:16:15	Identifying the Correct Candidates: The definition of resectable disease	G. Sapisochin
16:15-16:30	Identifying the Correct Candidates: Can molecular biology help?	C. O'Rourke
16:30-16:40	Immune and Molecular Profiling of Biliary Tract Cancer Treated with First-line Chemo-immunotherapy	R. Balsano
16:40-16:50	Circular RNAs in Cholangiocarcinoma: Mechanisms and biomarkers (a brief overview)	C. Coulouarn
16:50-17:15	PANEL DISCUSSION (with the addition of)	J. Primrose / A. Vogel
17:15-18:45	Poster Session and Presentation of Silver Award Recipients	Poster tour (A. Landa / E. Jarman
17:15-18:45	Precision-BTC-Net Management Committee Meeting (Invite Only)	











July 2nd		
TIME	TITLE	SPEAKER
08:45-9:00	WELCOME from the local committee	J. Kotlinowski / M. Krawczyk
9:00-10:30	A Patient-Centric Approach	
	CHAIRS	A. Forner / C. Braconi
09:00-09:15	Development of Patients' Contents: The AMMF experience	H. Morement
09:15-09:30	How to Start a Patients' Charity: The Spanish experience	E. Baucells
09:30-09:45	Sustainable Future of a Patients' Charity: The Italian experience	P. Leonardi
09:45-10:00	The Interaction of Patients' Charity with Pharma and Regulatory Bodies: The CCF experience	S. Lindsey
10:00-10:10	The Quality of Life in Biliary Tract Cancer Patients: The current state and where we are headed	L. Cavka
10:10-10:35	PANEL DISCUSSION (with the addition of)	P. Martin / G. Iserte
10:35-11:00	COFFEE BREAK	
11:00-12:30	The Potential of Artificial Intelligence in Guiding BTC Management	
	CHAIRS	J. Andersen / L. Fabris
11:00-11:15	European Molecular Registry of Cholangiocarcinoma: An update	J. Andersen
11:15-11:30	Artificial Intelligence for Clinical Cancer Research: Past, present, future	H. Muti
11:30-11:45	Integrating Digital Pathology and Spatial Genomics in Liver Cancer	S. Caruso
11:45-11:55	Radiomics in Intrahepatic Cholangiocarcinoma: Bridging gaps from data to evidence	L. Vigano
11:55-12:05	Application of Al in Early Diagnosis	S. Pereira
1.100 12100	Application of this Early Diagnosis	511 515.na
12:05-12:30	PANEL DISCUSSION (with the addition of)	B. Goeppert
12:30-13:00	ORAL PRESENTATIONS from Submitted Abstracts	
	CHAIRS	P. Acedo / R. Macias
	Gold Award recipient: The consequences of losing primary cilia in Intrahepatic Cholangiocarcinoma	S. Teles
	Gold Award recipient: Monocytes contribution to chemoresistance in Biliary Tract Cancer	F. Amato
	Gold Award recipient: Specific inhibition of PARP-1 preferentially impairs KRAS-mutated iCCA and is	D. Castven
	mediated by CHK1 kinase	
13:00-14:00	LUNCH	
14:00-15:30	Novel Pre-clinical Models to Support Drug Development	
	CHAIRS	M. Verstagen / T. Tian
14:00-14:15	Mcpip1 Knockout Mice as a New Model to Study Ductular Reaction	J. Kotlinowski
14:15-14:30	Modulating WNT/β-Catenin Pathway Activity as a Chemosensitive Strategy in Cholangiocarcinoma	E. Lozano
14:30-14:45	Exploiting CAF for Treatment in Cholangiocarcinoma	S. Marco
14:45-14:55	Using Patient-led Genetics to Identify Vew Metastatic Drivers in Cholangiocarcinoma	P. Olaizola
14:55-15:05	Syngeneic Ectopic Mouse Model of Cholangiocarcinoma to Test Innovative Physics-based Local Therapies	L. Fouassier
15:05-15:15	Novel Chemotherapeutic Agents in Biliary Cancer	F. Cossio
15:15-15:40	DISCUSSION (with the addition of)	C. Athanassopoulos / L. Boulter
15:40-16:00	CONCLUSIONS	

Silver Sponsors

**Gold Sponsor** 

**Bronze Sponsor** 









**LKB Biotech** 







